GlaxoSmithKline PLC has thrown its hat back into the oncology ring, specifically into the PARP inhibitor space, by making a $5.1bn bid to acquire Tesaro Inc..
The offer, which has been unanimously approved by Tesaro's board of directors, values the firm at $75 per share, representing a premium of around 60% over its closing price on Friday (Nov. 30) and 110% over its 30-day average price. The attraction of the Waltham, Mass
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?